FIXX - Homology's Inconclusive Data Leads To Highly Overvalued Stock - Price Target Of $5

The long awaited pheNIX Phase 1/2 first human data for Phenylketonuria (PKU) was finally released after the close December 17. (press release link) (slide show link) While appearing to show safety, Cohort 1 of two patients showed no efficacy at the low dose. Cohort 2 of n=2 (but only reporting one patient), is the source of some optimism and showed a trend towards efficacy. However, digging deeper into the rosy stats, charts and graphs it is very difficult to draw any real conclusion from this data. At $1 billion market cap ($270 million cash and